Home › Research › How common it is
Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo
Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S et al.. Proceedings of the National Academy of Sciences of the United States of America, 2001-04-10
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Recent epidemiological studies show a strong reduction in the incidence of Alzheimer's disease in patients treated with cholesterol-lowering statins. Moreover, elevated Abeta42 levels and the varepsilon4 allele of the lipid-carrier apolipoprotein E are regarded as risk factors for sporadic and familial Alzheimer's disease. Here we demonstrate that the widely used cholesterol-lowering drugs simvastatin and lovastatin reduce intracellular and extracellular levels of Abeta42 and Abeta40 peptides in primary cultures of hippocampal neurons and mixed cortical neurons. Likewise, guinea pigs treated with high doses of simvastatin showed a strong and reversible reduction of cerebral Abeta42 and Abeta40 levels in the cerebrospinal fluid and brain homogenate. These results suggest that lipids are playing an important role in the development of Alzheimer's disease. Lowered levels of Abeta42 may provide the mechanism for the observed reduced incidence of dementia in statin-treated patients and may open up avenues for therapeutic interventions.
What this study adds
Evidence grade: Low
The authors propose that lower Abeta42 "may provide the mechanism" for the reduced dementia rates reported in statin users by earlier population studies, but this paper studied no people and measured no memory or dementia outcomes. These are laboratory and animal results that the authors say "may open up avenues for therapeutic interventions"; they do not show that statins prevent or treat Alzheimer's.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., et al. (2001). Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. https://doi.org/10.1073/pnas.081620098
Vancouver
Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2001. doi:10.1073/pnas.081620098. PMID: 11296263.
BibTeX
@article{fassbender2001-11296263,
author = {Fassbender, K. and Simons, M. and Bergmann, C. and Stroick, M. and Lutjohann, D. and Keller, P. and Runz, H. and Kuhl, S. and others},
title = {{Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo}},
journal = {Proceedings of the National Academy of Sciences of the United States of America},
year = {2001},
doi = {10.1073/pnas.081620098},
pmid = {11296263},
url = {https://doi.org/10.1073/pnas.081620098}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- These results suggest that lipids are playing an important role in the development of Alzheimer's disease.
Why it matters
In nerve cells grown in the lab, the cholesterol-lowering drugs simvastatin and lovastatin lowered levels of the amyloid-beta peptides Abeta42 and Abeta40; in guinea pigs given high doses of simvastatin, these levels fell in cerebrospinal fluid and brain and the fall was reversible. The authors propose that lower Abeta42 "may provide the mechanism" for the reduced dementia rates reported in statin users by earlier population studies, but this paper studied no people and measured no memory or dementia outcomes. These are laboratory and animal results that the authors say "may open up avenues for therapeutic interventions"; they do not show that statins prevent or treat Alzheimer's.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Evidence strengthLow
How this study scored 54/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Proceedings of the National Academy of Sciences of the United States of America) |
| Journal's citation record | 4 / 4 | Proceedings of the National Academy of Sciences: journal h-index 1,167 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2001 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “in vitro”) — scores zero |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,092 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 40.4 citations a year over 27 year(s) since 2001 |
| Impact for its field and year | 6 / 6 | Cited 49.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 43 other studies in this library |
| Still being cited | 2 / 4 | Cited 34 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Tobias Hartmann: h-index 69 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Heidelberg University: institution h-index 1,344 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 11296263) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
43 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in How common it is from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.